Anifrolumab

Anifrolumab[1] is a monoclonal antibody designed for the treatment of systemic lupus erythematosus (SLE).[2] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.

Anifrolumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetInterferon α/β receptor
Clinical data
Routes of
administration		Intravenous
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6444H9964N1712O2018S44
Molar mass145119.20 g·mol−1

The drug was developed by MedImmune, a unit of AstraZeneca, which chose to move anifrolumab instead of sifalimumab into phase III trials for lupus in 2015.[3][4][5]

Clinical trial results

Anifrolumab failed to meet its endpoint of significant reduction in disease as assessed by the SLE Responder Index 4 instrument in the TULIP 1 phase III trial.[6] This multi-center, double-blind, placebo-controlled study followed adults with moderate to severe SLE over the course of one year. Preliminary results were announced on 31 August 2018.

Adverse effects

The most common adverse effect was shingles, which occurred in 5% of patients in the low-dose group, to 10% in the high-dose group, and to 2% in the placebo group. Overall adverse effect rates were comparable in all groups.[7]

gollark: But "everything ever" includes BAD THINGS!
gollark: So far as I can tell you need to explicitly click "publish" for it to be broadcast.
gollark: I wanted to publish https://discord.com/channels/346530916832903169/346531686663716875/678265280895647774.
gollark: How come it won't let me "publish" messages from <#346531686663716875>?
gollark: :(

References
  1. World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
  2. Statement On A Nonproprietary Name Adopted By The USAN Council - Anifrolumab, American Medical Association.
  3. "Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017.
  4. "Anifrolumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017.
  5. "Anifrolumab". AdisInsight. Retrieved 31 July 2017.
  6. "Update on TULIP 1 Phase III trial for anifrolumab in systemic lupus erythematosus". www.astrazeneca.com. Retrieved 2019-02-05.
  7. H. Spreitzer (29 August 2016). "Neue Wirkstoffe - Anifrolumab". Österreichische Apothekerzeitung (in German) (18/2016).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.